Pasithea Therapeutics (KTTAW) to Release Earnings on Wednesday

Pasithea Therapeutics (NASDAQ:KTTAW) is projected to issue its resultson Wednesday, June 3rd. Analysts expect Pasithea Therapeutics to post earnings of ($3.40) per share and revenue of $0.30 million for the quarter.

Pasithea Therapeutics Stock Up 19.6%

KTTAW opened at $0.01 on Wednesday. The business has a 50-day moving average of $0.01 and a 200-day moving average of $0.01. Pasithea Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.12.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia.